Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence-Reference-Cited by-同舟云学术

Comparative efficacy and safety of traditional Chinese patent medicine for NAFLD in childhood or adolescence

Published:2021-01-22 Issue:3 Volume:100 Page:e24277
ISSN:0025-7974
Container-title:Medicine
language:en
Short-container-title:

Author:

Sun Yuli,Tan Zhaofeng,Jiang Zhenyuan,Li Min,Wang Weiqin,Huang Yaoyao,Sun Jianguang

Funder

Chinese Medicine Science and Technology Development Project of Shandong Province, China

Collaborative Innovation Center for Modern Science and Technology and Industrial Development of Jiangxi Traditional Medicine

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

General Medicine

Reference26 articles.

1. A guide to non-alcoholic fatty liver disease in childhood and adolescence;Temple;Intern J Mol Sci,2016

2. Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010;Welsh;J Pediatr,2013

3. The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis;Anderson;Plos One,2015

4. Nonalcoholic fatty liver disease, liver fibrosis, and cardiometabolic risk factors in adolescence: a cross-sectional study of 1874 general population adolescents;Lawlor;JClinEndocrinolMetab,2014

5. Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment;Alisi;Ann Med,2012

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Costunolide Prevents Free Fatty Acid-Induced Hepatocyte Steatosis by Activating the Autophagy Pathway;J BIOL REG HOMEOS AG;2024

2. Dietary and Nutritional Interventions in Nonalcoholic Fatty Liver Disease in Pediatrics;Nutrients;2023-11-18

3. Integrated strategy of RNA-sequencing and network pharmacology for exploring the protective mechanism of Shen-Shi-Jiang-Zhuo formula in rat with non-alcoholic fatty liver disease;Pharmaceutical Biology;2022-09-20